Fixed combination of vilanterol triphenatate/fluticasone furoate in the treatment of patients with bronchial asthma and chronic obstructive pulmonary disease: a literature review

Abstract

A review of the literature selected from russian and foreign electronic medical libraries devoted to the use of a fixed combination of fluticasone furoate with vilanterol triphenatate (FF/VI) in the respiratory tract using a metered-dose powder inhaler in bronchial asthma (BA) and chronic obstructive pulmonary disease (COPD) is presented. (DPI) Ellipt. The results of studies of each of  the  components devoted to their clinical efficacy and safety, and the  use of  FF / VI in  asthma  and COPD are presented. Comparative randomized clinical trials have shown the advantages of FF / VI over the individual components of this combination and over other drugs. This combination was especially effective in AD. The economic efficiency of the transition of BA patients from everyday therapy to FF/VI has been proved. The data on the ability of the Ellipt DPI to form a clinically significant portion of the respirable fraction of both drugs, as well as data on the intuitive use of the device and adherence to the prescribed therapy are presented. In terms of the development of adverse events, the use of this combination in AD did not differ from placebo. With the use of FF/VI in patients with COPD, an increased incidence of pneumonia was noted, which was also typical for the use of FF alone, but did not accompany treatment with vilanterol. The analysis of the literature data based on well-planned multicenter RCTs with a large number of patients showed that the expansion of the use of a fixed combination of FF/VI in AD and COPD can improve control over these diseases and reduce the costs of practical healthcare, as well as preserve the level of treatment safety in comparison with monotherapy.